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To date, over 30 genes with mutations causing limb-girdle muscle dystrophy have been 
described. Dysferlinopathies are a form of limb-girdle muscle dystrophy type 2B with an 
incidence ranging from 1:1,300 to 1:200,000 in different populations. In 1996, Dr. S. N. 
Illarioshkin described a family from the Botlikhsky district of Dagestan, where limb-girdle 
muscle dystrophy type 2B and Miyoshi myopathy were diagnosed in 12 members from 
three generations of a large Avar family. In 2000, a previously undescribed mutation in 
the DYSF gene (c.TG573/574AT; p. Val67Asp) was detected in the affected members of 
this family. Twenty years later, in this work, we re-examine five known and seven newly 
affected family members previously diagnosed with dysferlinopathy. We observed dis-
ease progression in family members who were previously diagnosed and noted obvious 
clinical polymorphism of the disease. A typical clinical case is provided.
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INtRoDUCtIoN
In 1996, a group of doctors from the Research Institute of Neurology (Russian Academy of Medical 
Science), described an Avar family originating in a Dagestan mountain village with nine members 
diagnosed with limb-girdle muscle dystrophy type 2B (LGMD2B) and three members diagnosed 
with Miyoshi myopathy. Subsequently, a mutation in exon 3 c. 573–574 TG>AT of the DYSF gene 
in a homozygous state with a substitution p. Val67Asp was identified in every affected member of 
the family (1, 2).
The gene DYSF consists of 55 exons and has a size of 150,000 bp (3). Dysferlin is an integrated 
transmembrane protein with expression widely distributed throughout an organism. It is expressed 
in striated and cardiac muscle, brain, spleen, small intestine, placenta, and monocytes and is 
expressed in lower amounts in the liver, lungs, kidneys, and pancreas (4). Matsuda et al. determined 
that dysferlin interacted with calpain-3 and promoted membrane repair (5). The lack of dysferlin 
or its insufficient activity results in impaired membrane repair in muscle fibers and, consequently, 
in its destruction and loss followed by increased blood creatine phosphokinase (CPK) levels (6). 
Abbreviations: bp, base pairs; CPK, creatine phosphokinase; ENMG, electroneuromyography; LGMD, limb-girdle muscular 
dystrophy; MUAP, motor unit action potentials.
FIGURe 1 | simplified pedigree of Family a. Symbols in black represent patients with a LGMD phenotype; those in gray represent patients with a phenotype of 
distal myopathy. Underlined symbols highlight previously diagnosed patients.
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Thus, insufficient functional dysferlin leads to necrotic changes 
and fibrosis in muscles that progress to loss of muscle strength in 
affected individuals (7). The presence of two (2) or even three dif-
ferent (8) clinical phenotypes in patients with the same mutation 
of DYSF remains unexplained.
The purpose of this study was to evaluate disease progression 
in patients with dysferlinopathy described in 1996 and to study a 
clinical pattern in affected family members with newly diagnosed 
dysferlinopathy.
patIeNts aND MetHoDs
patients
Twelve patients (nine males and three females) were examined. 
Five patients originated from the largest branch of the same fam-
ily (A), which has had manifestations of limb-girdle muscular 
dystrophy (LGMD) within six generations and were previously 
described by Illarioshkin et al. (Figure 1). An LGMD phenotype 
was detected in two patients (A III-19 and A III-20), distal Miyoshi 
myopathy—in two patients (A III-26 and A IV-7), and asympto-
matic increased serum CPK activity levels and electromyographic 
(EMG) signs of primary muscle disease in one patient (A IV-11). 
The same mutation in the DYSF gene in a homozygous state 
[TG573/574AT (Val67Asp)] was identified in every patient. All 
of the patients are close relatives.
All procedures were performed after patients signed a volun-
tary informed consent form, as required by the Declaration of 
Helsinki (2013) and the local Ethics Committee (Dagestan State 
Medical Academy, Makhachkala, Russia).
Clinical, Genealogical, and Neurological 
examination
Five previously diagnosed and seven newly diagnosed patients 
(A IV-2, A IV-12, B-1, C-1, D-1, E-1, and E-2) underwent clini-
cal and genealogical analyses and a neurological examination 
(Table 1).
Laboratory and Instrumental Methods
Blood serum CPK activity testing was performed in 12 patients. 
Nerve conduction study and needle electromyography were per-
formed in three patients (A IV-2, C-1, and D-1). MRI of lower 
extremity muscles (T1, T2, STIR) was performed in two patients 
(A IV-2, C-1).
Histological and Immunohistochemical 
analyses
Histological and immunohistochemical analyses were performed 
for one patient (D-1). A fragment (5 mm3) of a lateral portion 
of the quadriceps femoris muscle was sampled and prepared 
using the standard procedure; longitudinal and cross-sections 
of the specimens were stained with hematoxylin and eosin. 
Immunohistochemistry was carried out with antibodies to 
dysferlin, dystrophin, alpha-smooth muscle actin, Ki67, CD68, 
CD4, and CD8.
taBLe 1 | summarized examination results of patients with dysferlinopathy.
patient a III-19 a III-20 B-1 a III-26 a IV-7 a IV-11 a IV-12 a IV-2 C-1 D-1 e-1 e-2
Age at onset, years 16 18 17 21 15 15 28 18 17 19 16 15
Age at examination (1993), years 43 41 4 23 23 6 8 10 8 3 2 5
Age at examination (2013), years 63 61 24 40 42 26 28 30 28 22 22 25
Duration of a disease, years 47 43 7 19 27 11 1 12 11 3 6 10
Phenotype (pattern manifested) Limb-girdle 
muscular dystrophy 
(LGMD)
LGMD LGMD Miyoshi Miyoshi Miyoshi Miyoshi Miyoshi Prox-distal Prox-distal Miyoshi Miyoshi
Current dominant pattern Prox-distal UL LL Prox-distal 
UL LL
Prox-distal 
UL LL
Dist.-prox 
UL LL
Dist.-prox 
UL LL
Dist. -prox 
UL LL
Dist.-
prox UL
Dist.-prox 
UL LL
Prox-distal 
UL LL
Prox-distal 
UL
Dist.-prox 
UL LL
Prox-distal 
UL LL
ta/G 4/5 4/5 3/3 4/3 3/3 2/3 1/2 2/2 –/1 2/2 3/2
QF/pF 5/5 5/5 3/4 3/4 3/4 1/2 1/1 –/1 –/2 1/3 1/3 1/3
MG 4 4 2 1 1 – – – 1 – 2 3
Da 3 4 1 3 3 2 – 2 2 1 2 2
B 5 4 1 3 2 – – 2 3 – 1 3
D + s 4 4 – 1 – – – – – – – 2
es 2 2 – 1 – – – – – – – –
Atrophy TA, G, QF, PF, MG, 
DA, B, D, S, ES
TA, G, QF, PF, 
MG, DA, B, D, 
S, ES
TA, G, QF, 
PF, DA, B
TA, G, QF, PF, 
MG, DA, B, 
D, S
TA, G, QF, PF, 
DA, B
G, PF, DA G TA, G, 
DA, B
G, PF, 
DA, B
TA, G, PF, 
DA
TA, G, QF, 
PF, MG, 
DA, B
TA, G, QF, PF, 
MG, DA, B, D, S
Contractures AC AC – AC AC – – – – – AC AC
No refl. Abs Abs KR, AR KR, AR KR, AR AR AR KR, AR Abs AR KR, AR KR, AR
Motor performance IC IC WG, GM AbAI Steppage AbAI Normal AbAI AbAI, GM Steppage Steppage WG, steppage
TA, m. tibialis anterior; G, m. gastrocnemius; QF, m. quadriceps femoris; PF, posterior femoral muscles; MG, mm. glutei; DA, distal upper limb muscle; B, m. biceps brachii; D, m. deltoideus; S, muscles of scapula; ER, m. erector 
spine; Abs, absence of reflexes; AR, Achilles reflex; KR, knee reflex; AC, contracture of Achilles tendon; IC, invalid wheel-chair; AbAI, able to ambulate independently; WG, waddling gait, GM, Gowers’ manoeuvres; UL, upper limbs, LL, 
lower limbs. In bold frame: muscle power according to MRC scale. The patients previously examined by Illarioshkin et al. (1) are marked in gray.
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FIGURe 2 | Patient C-1, age 28 with distal Miyoshi myopathy (a) and 
magnetic resonance images (t2-WI) at the level of the middle third of 
the thigh (B) and lower leg (C).
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Genetic analysis
A genetic defect was confirmed by PCR with diagnostic primers 
to a previously known mutation.
statistical analysis
The results of the morphometric analysis are presented as the 
mean ± SD. Significant changes were assessed by Student’s t-test, 
with P < 0.05 as the level of significance.
ResULts
Clinical and Genealogical analyses
Five generations of Family A had 15 members with signs of pro-
gressive muscular dystrophy, four intermarriages were identified. 
Parents and known relatives of five newly diagnosed patients (B-1, 
C-1 (Figure 2), D-1 (Figure 3), E-1, and E-2) from four other 
families were clinically healthy. Autosomal recessive inheritance 
of progressive muscular dystrophy was determined.
Neurological examination
A Miyoshi phenotype characterized by primary isolated weakness 
in distal regions of legs was identified in seven (58%) patients. 
A phenotype of LGMD characterized by predominant weak-
ness in femoral and pelvic girdle muscles (difficult standing up, 
waddling gait) was identified in three (25%) patients. Two (16%) 
patients had proximal–distal phenotype with muscle weakness 
equally affecting both proximal and distal regions of the lower 
extremities. Subsequently, muscle weakness and amyotrophy 
extended upwards.
The mean age of all patients at examination was 34.3 ± 14.4 years 
(22–62  years). The mean age of symptom onset in all patients 
occurred during the late teens and was 17.9 ±  3.6  years (15–
28 years). All patients had normal physical and mental develop-
ment within the period preceding disease onset.
Re-examined patients with previously 
Diagnosed Dysferlinopathy
Two (A III-19, A III-20) out of five previously examined patients 
had the LGMD phenotype with normal distal strength due to a 
proximal myopathy beginning at age 16–18 years. At the age of 41 
and 43, both patients presented severe generalized distal weakness 
with minimal movements in distal regions of the extremities and 
diffuse atrophy in neck extensors. Upon re-examination at the age 
of 61 and 63, both patients had severe generalized manifestations 
of myopathy and were unable to ambulate independently. Both 
patients had total areflexia and significant contractures in ankle 
joints, but intact muscles of the face, throat, and sphincters.
Most patients with LGMD (A II-2, A III-3, A III-5, A III-6, A 
III-11, A III-12) described by Illarioshkin et al. (1) had similar 
progression, distribution of muscle weakness, and atrophy. 
They lost their ability to ambulate independently at the age of 
40.4 ± 5.4 years (30–45 years).
One patient (A IV-11) was followed up from the age of 6 to 
11 without clinical manifestations of myopathy, although he 
had a threefold increase in the CPK activity level (580 U/L) and 
intramuscular EMG signs of primary muscle damage (Research 
Center of Neurology, RAMS). On re-examination at the age of 
26, he presented specific symptoms of distal Miyoshi myopathy 
with paresis and atrophy of the calf muscles. His elder brother 
(A IV-7) was diagnosed at the age of 23 with the Miyoshi pheno-
type, which had manifested when he was 16. When re-examining 
him at the age of 42, we observed marked atrophies and paresis 
of lower leg muscles and moderate weakness in hamstrings. 
Atrophy and weakness were more pronounced in the forearm 
flexors and less evident in the biceps muscles of upper arms, pre-
sumably associated with active engagement in freestyle wrestling 
at the age of 20–25.
The third patient (A III-26) with the Miyoshi phenotype 
determined at the age of 23 was also examined. The disease 
manifested at the age of 20, when re-examined at the age of 40, the 
patient’s severe generalized weakness was worse in the legs. The 
patient had Achilles tendon contractures and no knee or Achilles 
reflexes, but was able to walk with support.
patients with Newly Diagnosed 
Dysferlinopathy
The mean age of new patients at examination was 34.3 ± 14.4 years 
(22–62 years). The mean age of symptom onset was 17.9 ± 3.6 years 
(15–28 years).
Among the new patients diagnosed, four (A IV-2, A IV-12, 
E-1, E-2) had a Miyoshi phenotype, two (C-1 and D-1) a 
 proximal–distal phenotype, and one (B-1) a LGMD phenotype. 
The mean age at disease onset in patients with the Miyoshi 
FIGURe 3 | Patient D-1, age 22 with the proximal-distal phenotype (a); microslides of m. vastus lateralis byopsy samples: hematoxylin and eosin staining 
(B,C); an immunohistochemical reaction with anti-dysferlin antibodies (D,e). The loss of cross-striation, a destruction of some muscle fibers and massive histiocytic 
infiltration.
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phenotype was 19.3 ± 5.9 years (15–28 years), and the mean age 
at examination was 26.3 ± 3.5 years (22–30 years). One patient 
(A IV-12) complained at disease onset of weakness in the calves 
for 1 year that manifested as difficulty standing up on the heels; 
however, a neurological examination revealed a slightly reduced 
strength in the posterior muscles of the thighs. All patients with 
a disease duration ranging from 3 to 10 years (n = 4, 66%) had 
more pronounced distal–proximal myogenic paresis in the 
lower extremities and mild paresis in the upper extremities with 
involvement of m. biceps brachii.
One re-examined patient (E-2) with the Miyoshi phenotype 
had comparatively rapid progression with extension into proximal 
regions of the upper extremities and upper limb-girdle muscles. 
Two patients (C-1 and D-1) had a proximal–distal phenotype due 
to parallel progression of weakness and muscle atrophy of both 
distal and proximal regions of the lower extremities with sub-
sequent involvement of the upper extremities as in the Miyoshi 
phenotype.
Subacute myogenic proximal–distal paraparesis of the lower 
extremities that developed after running (see Case Report) 
was a hallmark of the dysferlinopathy onset in Patient D-1. All 
the patients are able to ambulate independently, with steppage 
observed in 50% of cases due to weakness and atrophy in anterior 
muscle compartments of the lower leg or diffuse impairment of 
all of the calf muscles. Knee and Achilles reflexes were absent in 
all of the patients. Achilles tendon contractures were observed in 
two patients (E-1, E-2).
One patient (B-1) had the LGMD phenotype, manifested at 
the age of 17. A neurologic examination of the patient at age 24 
found severe generalized weakness, which was worse in legs.
The summarized examination results for the patients are given 
in Table 1.
electromyographic
Two patients (A IV-2, D-1) had nerve conduction study and 
needle electromyography performed. Normal conduction veloc-
ity was recorded along all of the nerves of the arms and legs, 
with a slightly decreased M-response amplitude. Needle electro-
myography did not record any spontaneous activity of muscle 
fibers. Mainly short-duration motor unit action potentials were 
recorded, with an increased number of polyphasic potentials 
within the expected range for age in intact muscles (signs of 
primary muscle disease).
MRI of Lower extremity Muscles
Three patients (A IV-2, C-1, and D-1) aged 28, 30, and 23, respec-
tively, with a disease duration of 9.6 ±  3.2  years (6–12  years) 
received MRI of the lower limb. Decreased muscle volume, 
diffusely increased intensity of the MR-signal on T1-WI (pre-
dominantly) and T2-WI due to the infiltration of degenerated 
muscle by adipose, and connective tissue were detected. Among 
the muscles of the lower leg, the earliest changes were typical for 
caput medialis m. gastrocnemius. The most pronounced changes 
were observed in m. gastrocnemius, m. soleus, and m. flexor 
6Umakhanova et al. Twenty-Year Progression of Dysferlinopathy
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digitorum longus and the least evident changes in the peroneal 
group and m. tibialis anterior. Among the muscles of the thigh, 
degenerative changes were more pronounced in caput longum m. 
biceps femoris and m. adductor magnus (a group of adductors) 
and less prominent in m. semitendinosus et semimembranosus 
and m. vastus lateralis.
Biochemical analysis
High serum CPK activity level up to 2,000–11,800 U/L (10- to 
60-fold to normal) prone to decrease with a patient’s age and 
disease duration was detected.
Histological and Immunohistochemical 
analyses
Histological and immunohistochemical analyses were performed 
for only one patient; the results are given in the Section “Case 
Report.” Immunohistochemical analysis of the patient’s muscle 
tissue identified of the lack of dysferlin expression in muscle 
fibers.
Genetic analysis
A previously identified mutation in the DYSF gene in a homozy-
gous state (c.TG573/574AT; p. Val67Asp) was verified in all the 
patients.
DIsCUssIoN
Three clinical patterns at the stage of disease debut were deter-
mined in 12 patients (old and new) from five closely related 
families originating from isolated mountainous settlements of 
the Republic of Dagestan: the distal Miyoshi phenotype (seven 
patients, 58.3%), the proximal–distal phenotype (two patients, 
16.6%), and the LGMD2B phenotype (three patients, 25%). Four 
intermarriages significantly contributed to the incidence of this 
autosomal recessive disorder.
There is a clear tendency toward the same phenotype within 
one generation of siblings, indicating the involvement of addi-
tional factors modifying expression of the DYSF gene. Similar 
peculiarities were previously reported for Japanese, Canadian, 
and Italian families with LGMD2B/Miyoshi (9–12) that confirm 
that there is no correlation between the phenotype and type 
of mutation. Based on recently published data, the presence of 
modifying genes (ANXA2 and ANXA1) affecting the outcome 
can be one possible explanation for this discrepancy.
Heterogeneity is specific for the age of manifestation and, 
therefore, for the period of asymptomatic disease. The mean 
age of disease onset for patients of every phenotype was 
17.9 ±  3.6  years, with the earliest manifestation occurring at 
the age of 15 as difficulty walking on the heels. Previous articles 
reported the debut of dysferlinopathy at the age of 47, as well as 
an asymptomatic disease until the age of 58, accompanied only 
by increased serum CPK activity levels (13, 14). Patient A IV-11, 
with an asymptomatic increased serum CPK activity level and 
EMG signs of primary muscle disease, had disease onset under 
the Miyoshi phenotype at age 15. This case confirms the presence 
of a latent course of dysferlinopathy and supports the possible 
use of EMG and CPK measurements for screening suspected 
homozygous carriers of mutations in the DYSF gene prior to 
clinical manifestation.
Case Report
A male patient at the age of 22 (D-1) with proximal–distal 
LGMD2B and a disease duration of 3  years is an example of 
a common diagnostic mistake associated with an acute or 
subacute onset of muscle weakness after exercise occasionally 
accompanied with pain and swollen legs. While in the army at 
the age of 19, the patient had subacute proximal paraparesis of 
the lower extremities; therefore, biopsy of m. vastus lateralis was 
performed. In addition to necrotized muscle fibers, lymphocytic 
infiltration of the endomysium was revealed and was interpreted 
as a manifestation of acute polymyositis, and corticosteroids 
were prescribed. The patient took them for 1½ year without any 
significant therapeutic effect. Knee and Achilles reflexes were 
absent. There were slight contractures of the Achilles tendons. 
A lack of dysferlin expression in muscle fibers was detected 
upon histological re-examination with immunohistochemistry. 
Corticosteroids were discontinued.
A genetic analysis identified the same missense mutation in 
exon 3 c. 573–574 TG>AT of the gene DYSF in a homozygous 
state with a substitution p. Val67Asp. This mutation is not found 
in electronic databases and has not been described in other 
studies of dysferlinopathy to enable an assumption of a common 
ancestor for members of these families.
CoNCLUDING ReMaRKs
In this work, an identical mutation confirming the fact of a 
common ancestor for patients from different families (A, B, 
C, D, E) with four intermarriages was identified. Patients 
with dysferlinopathy, both previously described and newly 
diagnosed were studied. This mutation, located in the DYSF 
gene, presented as three distinct phenotypes: distal Miyoshi, 
LGMD2B, and proximal–distal phenotype. Patients with a 
distal phenotype prevailed among those examined. Moreover, 
we also analyzed the dynamics of progression, sequence of 
involvement and intensity of the muscular dystrophic process 
in different groups of muscles over the past 20  years. In two 
cases (patients A IV-7 and D-1), disease onset was associated 
with physical activity. Therefore, we suggest that physical exer-
cise is an accelerating and enhancing factor for progression of 
a muscle dystrophy due to the direct role of dysferlin deficiency 
in repair disruption.
Similar studies will facilitate the development of distinct diag-
nostic criteria and provide guidance in optimal patient management 
by refining the selection of molecular and genetic methods used to 
verify a diagnosis and produce genetic prognoses for families.
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